PT - JOURNAL ARTICLE AU - Steven Riley AU - David Haw AU - Caroline E. Walters AU - Haowei Wang AU - Oliver Eales AU - Kylie E. C. Ainslie AU - Christina Atchison AU - Claudio Fronterre AU - Peter J. Diggle AU - Andrew J. Page AU - Alexander J. Trotter AU - Thanh Le Viet AU - Nabil-Fareed Alikhan AU - Justin O’Grady AU - The COVID-19 Genomics UK (COG-UK) Consortium AU - Deborah Ashby AU - Christl A. Donnelly AU - Graham Cooke AU - Wendy Barclay AU - Helen Ward AU - Ara Darzi AU - Paul Elliott TI - REACT-1 round 11 report: low prevalence of SARS-CoV-2 infection in the community prior to the third step of the English roadmap out of lockdown AID - 10.1101/2021.05.13.21257144 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.13.21257144 4099 - http://medrxiv.org/content/early/2021/05/17/2021.05.13.21257144.short 4100 - http://medrxiv.org/content/early/2021/05/17/2021.05.13.21257144.full AB - Background National epidemic dynamics of SARS-CoV-2 infections are being driven by: the degree of recent indoor mixing (both social and workplace), vaccine coverage, intrinsic properties of the circulating lineages, and prior history of infection (via natural immunity). In England, infections, hospitalisations and deaths fell during the first two steps of the “roadmap” for exiting the third national lockdown. The third step of the roadmap in England takes place on 17 May 2021.Methods We report the most recent findings on community infections from the REal-time Assessment of Community Transmission-1 (REACT-1) study in which a swab is obtained from a representative cross-sectional sample of the population in England and tested using PCR. Round 11 of REACT-1 commenced self-administered swab-collection on 15 April 2021 and completed collections on 3 May 2021. We compare the results of REACT-1 round 11 to round 10, in which swabs were collected from 11 to 30 March 2021.Results Between rounds 10 and 11, prevalence of swab-positivity dropped by 50% in England from 0.20% (0.17%, 0.23%) to 0.10% (0.08%, 0.13%), with a corresponding R estimate of 0.90 (0.87, 0.94). Rates of swab-positivity fell in the 55 to 64 year old group from 0.17% (0.12%, 0.25%) in round 10 to 0.06% (0.04%, 0.11%) in round 11. Prevalence in round 11 was higher in the 25 to 34 year old group at 0.21% (0.12%, 0.38%) than in the 55 to 64 year olds and also higher in participants of Asian ethnicity at 0.31% (0.16%, 0.60%) compared with white participants at 0.09% (0.07%, 0.11%). Based on sequence data for positive samples for which a lineage could be identified, we estimate that 92.3% (75.9%, 97.9%, n=24) of infections were from the B.1.1.7 lineage compared to 7.7% (2.1%, 24.1%, n=2) from the B.1.617.2 lineage. Both samples from the B.1.617.2 lineage were detected in London from participants not reporting travel in the previous two weeks. Also, allowing for suitable lag periods, the prior close alignment between prevalence of infections and hospitalisations and deaths nationally has diverged.Discussion We observed marked reductions in prevalence from March to April and early May 2021 in England reflecting the success of the vaccination programme and despite easing of restrictions during lockdown. However, there is potential upwards pressure on prevalence from the further easing of lockdown regulations and presence of the B.1.617.2 lineage. If prevalence rises in the coming weeks, policy-makers will need to assess the possible impact on hospitalisations and deaths. In addition, consideration should be given to other health and economic impacts if increased levels of community transmission occur.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Department of Health and Social Care in England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLinks to a spreadsheet, and the GitHub R pacakge containing supporting data for tables and figures are available within the manuscript.